NCT01464723View on ClinicalTrials.gov

Study EvAluating Genotypes While Using Lucentis 2

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

January 31, 2013

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

Ranibizumab

Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.

Trial Locations (1)

92093

Shiley Eye Center, University of California, San Diego, San Diego

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, San Diego

OTHER